PRINTO - Paediatric Rheumatology INternational Trials Organization

PRINTO ONGOING PROJECT DETAIL

Title

Description

MTX withdrawal in juvenile idiopathic arthritis

Treatment with the disease modifying anti-rheumatic drug methotrexate in dosages of 10–15 mg/m2 given once weekly has been proven to be safe and effective in Juvenile Idiopathic Arthritis, as well as etanercept. With this regime it is possible to achieve clinical remission on and off medication but the best time to stop MTX after remission has not yet been established.
The present trial was designed to determine if the time to discontinuation of methotrexate (6 versus 12 months) in Juvenile Idiopathic Arthritis, after the patient has reached clinical remission, influence the time to relapse, the clinical course and the predictors of flare.
If you are interested you can find some useful links below and/or you can contact the PRINTO office.
The complete set of information (material for ethics committee submission, protocols, consent forms, and case report forms) are available, for PRINTO members only, in the reserved Member area on the left.

ENROLLMENT TABLE

Related articles

Year

PubMed

Reprints

Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MAJ, Hollingworth P, Cawkwell G, Martini A, Ruperto N for the Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis. Analysis of the printo methotrexate trial. Ann Rheum Dis 201069:1479-1483.	2010
Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerß J, Stanevicha V, Mihaylova D, Ferriani V, Kanakoudi Tsakalidou F, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J, for the Paediatric Rheumatology INternational Trials Organization (PRINTO). Comparison of 6-month vs 12-month withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission: a randomized controlled trial. JAMA2010; 303(13):1266-1273	2010
Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, ShenYK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH, for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis2010:69(4):718-722	2010
Foell D, Frosch M, Zur Wiesch AS, Vogl T, Sorg C, Roth J Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis.2004; 63(2):206-208	2004
Wallace CA, Ruperto N, Giannini E Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol.2004 Nov;31(11):2290-4	2004

Back to "ongoing project"